Results for the Third Quarter 2021

Sales revenues for the quarter ended at MNOK 102.1 (MNOK 83.4), an increase of 22.5%. Sales as of September ended at MNOK 309.2 (MNOK 268.9) a 15.0% increase. Sales in the USA increased by 11.9…

Read more

Results for the First Quarter 2021

Sales for the quarter ended at MNOK 102.6 (MNOK 103.1), on par with the sales record set in Q1 last year. Currency neutral, sales increased by 1.5%. Second best quarter ever for operating result (EBIT)…

Read more

Annual Report 2020

Following a good start to the year, Medistim experienced a significant impact on operations in the first months of the pandemic. However, due to a solid revenue base and good pipeline activity throughout the second…

Read more

Results for the First Quarter 2020

Sales for the quarter ended at a record high MNOK 103.1 (MNOK 88.7), a 16.2% increase.This was driven by strong growth in capital sales of systems in Japan after regulatory approval of MiraQ™. Read the…

Read more

Annual Report 2019

We have now achieved a market penetration of 23% in USA, measured as the share of bypass procedures done with Medistim’s devices. Our position in Asia and Europe is also strengthened, through increased sales and…

Read more